发明申请
WO2007070105A1 IDENTIFICATION OF COMPOUNDS FOR INHIBITING COMPLEXATION OF C-REACTIVE PROTEIN WITH FIBRONECTIN
审中-公开
基本信息:
- 专利标题： IDENTIFICATION OF COMPOUNDS FOR INHIBITING COMPLEXATION OF C-REACTIVE PROTEIN WITH FIBRONECTIN
- 专利标题（中）：鉴定化合物抑制C反应蛋白与纤维蛋白复合物的化合物
- 申请号：PCT/US2006/026454 申请日：2006-06-30
- 公开(公告)号：WO2007070105A1 公开(公告)日：2007-06-21
- 发明人： BOGA, RameshBabu , MALIK, Sohail , QUIRK, Stephen
- 申请人： KIMBERLY-CLARK WORLDWIDE, INC. , BOGA, RameshBabu , MALIK, Sohail , QUIRK, Stephen
- 申请人地址： 401 N. Lake Street, Neenah, Wisconsin 54956 US
- 专利权人： KIMBERLY-CLARK WORLDWIDE, INC.,BOGA, RameshBabu,MALIK, Sohail,QUIRK, Stephen
- 当前专利权人： KIMBERLY-CLARK WORLDWIDE, INC.,BOGA, RameshBabu,MALIK, Sohail,QUIRK, Stephen
- 当前专利权人地址： 401 N. Lake Street, Neenah, Wisconsin 54956 US
- 代理机构： JOHNSTON, Jason, W.
- 优先权： US11/302,994 20051214
- 主分类号： G01N33/68
- IPC分类号： G01N33/68
摘要：
Disclosed are screening processes for identification of compounds that may inhibit complex formation between C-reactive protein and fibronectin. Compounds identified by the disclosed methods may be utilized to inhibit the target analytes that are known to occur during skin aging as well as during the course of several diseases. Accordingly, inhibitory compounds identified by the disclosed methods may be utilized to prevent and treat damaged tissue, inflammatory conditions, cardiovascular conditions, renal conditions, periodontal conditions and obesity, among other conditions. For example, the compounds identified by the disclosed methods may be utilized to treat tissue that has suffered trauma, e.g., burns or wounds, as well as tissue that is inflamed due to any of several causes. The disclosed compounds may also be utilized to improve the accuracy of assays designed to assess CRP or Fn levels in a sample, for instance in a plasma sample, as a risk assessment tool in certain medical conditions and to discover new treatments.
摘要（中）：
公开了用于鉴定可能抑制C-反应蛋白和纤连蛋白之间的复合物形成的化合物的筛选方法。 通过公开的方法鉴定的化合物可以用于抑制已知在皮肤老化期间以及在几种疾病过程中发生的目标分析物。 因此，通过所公开的方法鉴定的抑制性化合物可以用于预防和治疗受损组织，炎性病症，心血管病，肾病，牙周病和肥胖等疾病。 例如，通过公开的方法鉴定的化合物可用于治疗已经遭受创伤的组织，例如烧伤或伤口，以及由于几种原因中的任何一种而发炎的组织。 所公开的化合物还可以用于提高设计用于评估样品中的CRP或Fn水平的测定的准确度，例如在血浆样品中，作为某些医疗条件下的风险评估工具并发现新的治疗。